🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06756243
Starting soon Not applicable

The Use of Hydrogen Ion Water (Shan Shang Water) in the Treatment of Allergic Rhinitis

NCT06756243 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Started
2025-03-01
Last updated
2025-02-12

Condition(s) studied

Allergic Rhinitis

Investigational drug(s) / intervention(s)

Hydrogen Ion Water(Shan Shang Water)Budesonide Nasal Spray therapy

Hydrogen Ion Water(Shan Shang Water): Hydrogen Ion Water (also known as Hydrogen-Rich Water or Hydrogen Water) refers to water that contains dissolved hydrogen gas (H₂). Hydrogen gas is a powerful antioxidant that is believed to neutralize free radicals in the body, which may help reduce oxidative stress and improve overall health.

Budesonide Nasal Spray therapy: Budesonide Nasal Spray: Administered as 2 sprays twice daily (bid).

Study summary

The goal of this clinical trial is to evaluate whether Shan Shang Water (hydrogen ion water) can help treat allergic rhinitis in adults and affect immune markers.

Does Shan Shang Water reduce allergic rhinitis symptoms? What changes occur in immune markers when using Shan Shang Water? Researchers will compare Shan Shang Water to a placebo (an inactive substance) to see if it effectively treats allergic rhinitis.

Participants will:

Take Shan Shang Water or a placebo every day for 24 weeks. Visit the clinic every four weeks for checkups and tests. Record symptoms in a diary, noting things like sneezing, nasal congestion, and any use of medication.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Intermittent or persistent recurrent bouts of sneezing, watery nose, itchy and stuffy nose may be accompanied by eye symptoms including itchy, watery eyes, red and burning eyes, with or without wheezing, coughing, shortness of breath and chest tightness shape. * The symptoms are more severe or severe, and have a significant impact on quality of life. Exclusion Criteria: * Pregnant women and parturients. * Patients with liver, kidney and heart disease. * Patients with past or current tumors. * Specific immunotherapy, biologics, or small molecule drug therapy is planned or initiated.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06756243 on ClinicalTrials.gov ↗ ← All trials in China